4 Pearls for Managing Atopic Dermatitis

A new meta-analysis reveals monoclonal antibodies, including dupilumab, outperform placebo in treating moderate-to-severe atopic dermatitis.

KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.

Primary care is the ideal setting for management of atopic dermatitis, but certain scenarios, both physical and psychological, call for expert referral.

Novel AD therapies targeting OX40, IL-13, IL-36, IL-22, and IL-2 pathways show promise for disease modification and extended dosing intervals in phase 2-3 trials.

Treatment goals for atopic dermatitis among youth are diverse, emphasizing the need for tailored approaches based on age and disease severity, a new study suggests.

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.